Novartis pays €945m for eczema programmeEuropean biotechs Morphosys and Galapagos have handed over their joint atopical dermatitis programme MOR106 to Novartis for up to €945m. The Swiss pharma giant aims to strengthen its commitment to … more ➔
IMI to spur on antibiotics research amidst...The Innovative Medicines Initiative has launched a new Antimicrobial Resistance Accelerator Programme after Novartis announced its retreat from antibiotics research only days ago. more ➔
Roche granted breakthrough status for live...Roche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giants mAb combination therapy for liver cancer. more ➔
Epigenetic biomarkers predict immunotherap...UK biotech Oxford BioDynamics has presented data showing that the companys blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. more ➔
Urovant launches US$150m IPOSwiss biopharma company Urovant Sciences has launched its IPO on Nasdaq, seeking US$150m. The proceeds will go to Phase III trials for its overactive bladder treatment candidate vibegron. more ➔
Immunooncology: Genmab teams up with Immat...Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications. more ➔
Big Data: Tracking cancer risk genesUsing only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk. more ➔
Lifecare floats on Oslo stock exchangeNorwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor. more ➔
Abingworth closes new biotech fund at €2...Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US. more ➔
€47m for rare disease biotechAfter €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for … more ➔
